Kidney cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PD-1 21
• PD-L1 11
• VEGF 10
• mTOR 1
• AKT 0
• VHL 6
• PI3K 0
• PSMA 10
• STAT3 0
• BAP1 1
• TP53 0
• JAK 0
• CTLA-4 4
• STING 1
• ALK 1
• EGFR 3
• TFEB 0
• ERK 0
• MYC 0
• YAP 0
• HIF-1 0
• AMPK 0
• CTNNB1 0
• MET 2
• B7-H3 2
• MAPK 0
• PPAR 0
• FGFR 1
• GLP-1 0
• GPC3 3
• HER2 2
• IL-6 0
• MMP-9 0
• PARP 1
• AXL 1
• BCL-2 0
• EZH2 0
• IDH 1
• NTRK 0
• PTEN 0
• BRAF 1
• CD19 1
• CDKN2A 0
• JNK 0
• KRAS 1
• LAG-3 0
• METTL3 1
• NLRP3 0
• NRF2 0
• PKM2 0
• ROS1 0
• TNF 0
• APOE 0
• BRCA1 0
• BRCA2 0
• BRD4 0
• CD20 0
• CDK4/6 0
• DPP-4 0
• FOXP3 0

18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Defining how mitochondrial metabolites reprogram cellular metabolism to control tumor growth

  Northwestern University· Chicago, United States· US$99,022 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R50

  Research specialist award to support PDIGREE (A031704) and implementation of NCI supported clinical trials at Simmons Comprehensive Cancer Center

  Ut Southwestern Medical Center· Dallas, United States· US$164,513 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R44

  Clinical Validation of a Synthetic Biology-Based Microbial Medicine to Treat Immunotherapy Refractory Solid Tumors

  Rise Therapeutics, Llc· Rockville, United States· US$740,140 awarded in fiscal year 2026· until Aug 2029

• NIH NCI · R01

  Fasting mimicking diet and cancer stem cells in Wilms tumor

  Children's Hospital of Los Angeles· Los Angeles, United States· US$739,756 awarded in fiscal year 2026· until Aug 2031

• NIH NCI · R01

  Southern Community Cohort Study

  Vanderbilt University Medical Center· Nashville, United States· US$1,249,181 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Identification of TILs-specific novel lincRNA and their functional importance in mediating immune response in renal cell carcinoma (REGULINC)

  Turun Yliopisto· Turku, Finland· EU contribution €226,277· until Sept 2027

• European Commission (Horizon Europe) · HORIZON-ERC

  IDENTIfication and tracking of cancer-prone cells in KIdney Tubules (IDENTIKIT)

  Universita Vita-Salute San Raffaele· Milano, Italy· EU contribution €1,500,000· until Dec 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  TARGETING INHERITED CANCER SYNDROMES (INCANTAR)

  Fondazione Telethon Ets· Roma, Italy· EU contribution €2,496,625· until Aug 2028

• European Commission (Horizon Europe) · HORIZON-RIA

  First line randomized study platform to optimize treatment in patients with metastatic renal cell carcinoma (CARE1)

  Institut Gustave Roussy· Villejuif, France· EU contribution €5,577,694· until Apr 2028· 14 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  COMputational Models FOR patienT stratification in urologic cancers – Creating robust and trustworthy multimodal AI for health care (COMFORT)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €5,906,596· until Mar 2027· 7 countries

10 of 245 running projects, newest first. Listed amounts together: US$130.4m + €19.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC

  NCT07000149· AstraZeneca· Source

• A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

  NCT04522323· MedImmune LLC· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 37
• Organoids 4
• Mendelian Randomization Analysis 22
• CRISPR-Cas Systems 8
• Gene Expression Profiling 97
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 6
• Exome Sequencing 10
• Proteomics 25
• Metabolomics 12
• Mass Spectrometry 3
• Flow Cytometry 11
• Immunohistochemistry 95
• Liquid Biopsy 6
• Circulating Tumor DNA 8
• Xenograft Model Antitumor Assays 77
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 60
• Machine Learning 71
• Deep Learning 36
• Cohort Studies 67
• Genome-Wide Association Study 19

• Integrated single-cell and bulk transcriptomic analyses reveal ferro-aging-related molecular characteristics and immunological heterogeneity in renal cell carcinoma.

  PLoS One, Nov 2026

• Integrative Molecular Profiling and Single-Cell Characterization of LHFPL5 Reveal Cancer-Specific Regulatory Features in Clear Cell Renal Cell Carcinoma and Lung Adenocarcinoma.

  Medicina (Kaunas), Oct 2026

• Single-cell transcriptomics combined with Mendelian randomization reveals the pivotal role of WDR83OS in clear cell renal cell carcinoma: An observational and bioinformatic study.

  Medicine (Baltimore), Sept 2026

• Single-cell profiling of mitochondrial phenotyping-coupled mtDNA genotyping.

  Proc Natl Acad Sci U S A, Aug 2026

• Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.

  Nat Commun, Aug 2026

• Integrating single-cell analysis and machine learning algorithms to explore lactylation-related molecular mechanisms and therapeutic responses in clear cell renal cell carcinoma and identifying CDT1 as a potential biomarker.

  Front Endocrinol (Lausanne), Aug 2026

• Single-Cell and Machine Learning Analyses Identify MYDGF as an Immune-Related Biomarker Associated With the Tumor Microenvironment in Clear Cell Renal Cell Carcinoma.

  Hum Mutat, Jul 2026

• Bulk and single-cell transcriptome-based integrative analysis of an rRNA processing-related prognostic signature with functional validation of DDX47 in clear cell renal cell carcinoma.

  BMC Cancer, Jul 2026

• Computational analysis of bulk and single-cell RNAseq identifies prognostic signature genes in papillary renal cell carcinoma with Y chromosome loss.

  Comput Biol Med, Jun 2026

• Employing network toxicology, molecular docking, machine learning, and single-cell analysis to analyze BPA exposure-induced ccRCC.

  Biochem Biophys Res Commun, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.